Li Ge,Hongwen Yao,Rong Zhang,Xiaoguang Li,Ling-Ying Wu. Papillary serous carcinoma of the uterine cervix: a clinicopathological analysis of 4 cases and a literature review. Oncol Transl Med, 2017, 3: 197-202.
Papillary serous carcinoma of the uterine cervix: a clinicopathological analysis of 4 cases and a literature review
Received:June 17, 2017  Revised:November 07, 2017
View Full Text  View/Add Comment  Download reader
KeyWord:papillary serous carcinoma of uterine cervix (PSCC); clinicopathological features; prognosis analysis
Author NameAffiliationE-mail
Li Ge Department of Gynecologic Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China slwlaura@126.com 
Hongwen Yao Department of Gynecologic Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China  
Rong Zhang Department of Gynecologic Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China  
Xiaoguang Li Department of Gynecologic Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China  
Ling-Ying Wu Department of Gynecologic Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China wulingying@csco.org.cn 
Hits: 7400
Download times: 8661
Abstract:
      Objective To investigate the clinicopathological characteristics and clinical treatment outcomes of patients with papillary serous carcinoma of the uterine cervix (PSCC). Methods In this study, 4 patients with histologically confirmed papillary serous carcinoma of the uterine cervix were retrospectively investigated. Pap smears, human papillomavirus (HPV) screening, tumor marker status, biopsy analysis, and relevant imaging examinations were conducted for the confirmation of primary diagnosis and recurrence. Patients underwent surgery, chemotherapy, or radiotherapy, and survival were the main endpoint. Results The 4 patients were diagnosed with IB1, IB1, IIA, or IIIB disease. Two patients (2/4) presented with recurrence within 18 months after primary therapy. Compared with chemotherapy alone (progressionfree survival (PFS): 11 months), radiotherapy combined with adjuvant chemotherapy showed favorable PFS rates (PFS: 20, 36, 13 months in 3 cases), although valid statistical analysis was not feasible because of the small sample size. The 5-year survival rate was 0%, and the 3-year survival rate was 75%. Our data, in agreement with the literature evidence, showed that the number of moderate-risk and high-risk factors in patients diagnosed with PSCC at an early stage was higher than that in patients diagnosed with common adenocarcinoma/squamous carcinoma of the uterine cervix. Conclusion PSCC has a poor clinical prognosis, and compared with chemotherapy alone, radiotherapy combined with adjuvant chemotherapy may lead to improved PFS.
Close